BACKGROUND: Irradiation plays a pivotal role in head and neck squamous cell carcinoma (HNSCC) treatment. However, especially recurrent tumors frequently show increased radioresistance. We analyzed irradiation-stimulated mitogen-activated protein kinase (MAPK) signaling pathways to define cellular rescue mechanisms. METHODS: Irradiated HNSCC cells were screened for MAPK activation and results were confirmed and refined by functional analyses. Extracellular signal-regulated kinase (ERK) inhibitor U0126 application enabled us to specify postradiogenic cellular responses. Vascular endothelial growth factor (VEGF) levels were analyzed additionally. RESULTS: We observed a pronounced and time-dependent ERK stimulation. Pathway inhibition resulted in decreased radioresistance. Likewise, we found a decrease of VEGF release after inhibitor treatment. ERK activation was confirmed in xenotransplants showing elevated postradiogenic phospho-ERK (pERK) and VEGF levels. CONCLUSIONS: Our data give evidence for induction of ERK and successive VEGF release in HNSCC during radiotherapy, which might be partially explained by autoregulated cytoprotection maintained by pERK and potentially VEGF. In conclusion, targeting the ERK-VEGF axis might enhance the efficiency of radiotherapy.
BACKGROUND: Irradiation plays a pivotal role in head and neck squamous cell carcinoma (HNSCC) treatment. However, especially recurrent tumors frequently show increased radioresistance. We analyzed irradiation-stimulated mitogen-activated protein kinase (MAPK) signaling pathways to define cellular rescue mechanisms. METHODS: Irradiated HNSCC cells were screened for MAPK activation and results were confirmed and refined by functional analyses. Extracellular signal-regulated kinase (ERK) inhibitor U0126 application enabled us to specify postradiogenic cellular responses. Vascular endothelial growth factor (VEGF) levels were analyzed additionally. RESULTS: We observed a pronounced and time-dependent ERK stimulation. Pathway inhibition resulted in decreased radioresistance. Likewise, we found a decrease of VEGF release after inhibitor treatment. ERK activation was confirmed in xenotransplants showing elevated postradiogenic phospho-ERK (pERK) and VEGF levels. CONCLUSIONS: Our data give evidence for induction of ERK and successive VEGF release in HNSCC during radiotherapy, which might be partially explained by autoregulated cytoprotection maintained by pERK and potentially VEGF. In conclusion, targeting the ERK-VEGF axis might enhance the efficiency of radiotherapy.
Authors: Dominik Schuettler; Guido Piontek; Markus Wirth; Bernhard Haller; Rudolf Reiter; Gero Brockhoff; Anja Pickhard Journal: Am J Cancer Res Date: 2015-08-15 Impact factor: 6.166
Authors: Lei Chang; Peter Graham; Jingli Hao; Jie Ni; Junli Deng; Joseph Bucci; David Malouf; David Gillatt; Yong Li Journal: Oncotarget Date: 2016-03-08
Authors: Lei Chang; Jie Ni; Julia Beretov; Valerie C Wasinger; Jingli Hao; Joseph Bucci; David Malouf; David Gillatt; Peter H Graham; Yong Li Journal: Sci Rep Date: 2017-02-22 Impact factor: 4.379
Authors: Hanneke Stegeman; Johannes H A M Kaanders; Marieke M G Verheijen; Wenny J M Peeters; Deric L Wheeler; Mari Iida; Reidar Grénman; Albert J van der Kogel; Paul N Span; Johan Bussink Journal: Mol Cancer Date: 2013-11-05 Impact factor: 27.401
Authors: Valentina Bravatà; Claudia Cava; Luigi Minafra; Francesco Paolo Cammarata; Giorgio Russo; Maria Carla Gilardi; Isabella Castiglioni; Giusi Irma Forte Journal: Int J Mol Sci Date: 2018-04-04 Impact factor: 5.923